XY 4083

Drug Profile

XY 4083

Alternative Names: XY4083

Latest Information Update: 03 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xytis
  • Class Nootropics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 03 Mar 2010 Discontinued - Preclinical for Cognition disorders in USA (PO)
  • 18 Nov 2008 US FDA approves IND application for XY 4083 in Cognition disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top